Stocklytics Platform
Asset logo for symbol AXSM
Axsome Therapeutics
AXSM66
$131.15arrow_drop_down0.39%-$0.52
High Growth
Asset logo for symbol AXSM
AXSM66

$131.15

arrow_drop_down0.39%

Income Statement (AXSM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$62.62M-$80.03M-$67.27M-$98.27M-$64.20M
EBITDA-$60.56M-$78.04M-$65.44M-$96.53M-$62.12M
gross Profit$96.32M$79.11M$66.87M$64.15M$51.26M
NET Income-$64.60M-$79.34M-$68.35M-$98.65M-$62.19M
total Revenue$104.76M$87.16M$74.99M$71.53M$57.79M

Balance Sheet (AXSM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$135.04M-$123.85M-$142.01M-$199.82M-$230.98M
stockholders Equity$92.89M$102.85M$144.03M$190.97M$269.50M
total Assets$561.45M$548.22M$545.72M$588.23M$600.85M
total Debt$192.30M$191.80M$189.42M$186.37M$185.57M
total Liabilities$468.56M$445.37M$401.69M$397.25M$331.34M

Cash Flow (AXSM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$30.40M$14.37M-$1.18M-$2,000.00$33.37M
free Cash Flow-$18.48M-$30.16M-$53.56M-$30.36M-$53.91M
investing Cash Flow-----$371.00K
operating Cash Flow-$18.63M-$30.11M-$53.46M-$30.36M-$53.54M

Axsome Therapeutics (AXSM) Financials

Axsome Therapeutics Inc (AXSM) is a biopharmaceutical company that focuses on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company's income statement reflects its financial performance over a specified period of time, usually a year. It provides a summary of revenues, expenses, and net income. In the case of Axsome Therapeutics Inc, the income statement shows the company's total revenue, gross profit, operating income, and net income from stockholders. These figures give investors insights into the company's profitability and financial health.
Earnings before interest and taxes (EBIT) is a measure of a company's profitability that takes into account both its revenue and expenses, excluding interest and taxes. EBITDA, on the other hand, stands for earnings before interest, taxes, depreciation, and amortization. It provides a more comprehensive view of a company's profitability by accounting for non-cash expenses such as depreciation and amortization. Both EBIT and EBITDA are important indicators of a company's financial performance, as they show its ability to generate profits from its operations. For Axsome Therapeutics Inc, these figures are crucial in assessing the company's financial performance and its ability to generate sustainable profits.
The balance sheet of Axsome Therapeutics Inc provides a snapshot of the company's financial position at a specific point in time. It lists the company's assets, liabilities, and stockholders' equity. Some key components of the balance sheet include cash equivalents, net debt, stockholders' equity, total assets, total debt, and total liabilities. Cash equivalents refer to highly liquid assets that can be easily converted into cash, such as short-term investments. Net debt is calculated by subtracting cash and cash equivalents from total debt. Stockholders' equity represents the ownership interest of the company's shareholders. Total assets indicate the value of the company's resources, while total debt and total liabilities represent its obligations. These figures are crucial for assessing the financial health and stability of Axsome Therapeutics Inc.
Cash flow refers to the movement of cash in and out of a company. It is divided into three categories: operating cash flow, investing cash flow, and financing cash flow. Operating cash flow represents the cash generated or used by a company's core operations. Investing cash flow refers to the cash flows related to the acquisition or disposal of long-term assets, such as property, plant, and equipment. Lastly, financing cash flow includes the cash flows related to the company's financing activities, such as issuing or repurchasing stock and borrowing or repaying debt. The cash flow statement is important for understanding a company's ability to generate and manage its cash flows. For Axsome Therapeutics Inc, analyzing its cash flow is crucial for evaluating its liquidity and financial stability.
In conclusion, Axsome Therapeutics Inc's financials play a significant role in evaluating the company's financial performance, profitability, liquidity, and overall financial health. Understanding its income statement, EBIT, EBITDA, gross profit, balance sheet, cash equivalents, net debt, stockholders' equity, total assets, total debt, total liabilities, and cash flow is crucial for making informed investment decisions.
add Axsome Therapeutics  to watchlist

Keep an eye on Axsome Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level